Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Malignancy after renal transplantation: the role of immunosuppression.

Rama I, Grinyó JM.

Nat Rev Nephrol. 2010 Sep;6(9):511-9. doi: 10.1038/nrneph.2010.102. Review.

PMID:
20736984
2.
3.

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Gutierrez-Dalmau A, Campistol JM.

Drugs. 2007;67(8):1167-98. Review.

PMID:
17521218
4.

[Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].

Infante B, Stallone G, Schena A, Maiorano A, Gesualdo L, Schena FP, Grandaliano G.

G Ital Nefrol. 2006 Jul-Aug;23(4):389-95. Review. Italian.

PMID:
17063439
5.

Urological malignancy after renal transplantation.

Besarani D, Cranston D.

BJU Int. 2007 Sep;100(3):502-5. Review.

6.

Patient survival after renal transplantation; more than 25 years follow-up.

Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA.

Nephrol Dial Transplant. 1997 Aug;12(8):1672-9.

PMID:
9269647
7.

Risk factors for and management of post-transplantation cardiovascular disease.

Fellström B.

BioDrugs. 2001;15(4):261-78. Review.

PMID:
11437691
8.

The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy.

Ondrus D, Pribylincová V, Breza J, Bujdák P, Miklosi M, Reznícek J, Zvara V.

Int Urol Nephrol. 1999;31(4):417-22.

PMID:
10668934
9.

[Risk of cancer in patients following chronic dialysis and kidney graft].

Janus N, Launay-Vacher V, Ferrero JM, Thariat J.

Bull Cancer. 2012 Mar 1;99(3):285-93. doi: 10.1684/bdc.2012.1545. Review. French.

10.

Epidemiological profile of nonmelanoma skin cancer in renal transplant recipients: experience of a referral center.

Ferreira FR, Ogawa MM, Nascimento LF, Tomimori J.

An Bras Dermatol. 2014 Sep-Oct;89(5):745-50.

11.

Belatacept for kidney transplant recipients.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD010699. doi: 10.1002/14651858.CD010699.pub2. Review.

PMID:
25416857
12.

Cancer incidence after immunosuppressive treatment following kidney transplantation.

Andrés A.

Crit Rev Oncol Hematol. 2005 Oct;56(1):71-85. Review.

PMID:
15978827
13.

Risk of malignancy with long-term immunosuppression in renal transplant recipients.

Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB.

Kidney Int. 2004 Jul;66(1):383-9.

14.

Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.

Tsai SF, Cheng CY, Shu KH, Wu MJ.

Transplant Proc. 2012 Jan;44(1):190-2. doi: 10.1016/j.transproceed.2011.12.018.

PMID:
22310612
15.

Renal transplantation, immunosuppression and the skin: an update.

Moloney FJ, de Freitas D, Conlon PJ, Murphy GM.

Photodermatol Photoimmunol Photomed. 2005 Feb;21(1):1-8. Review.

PMID:
15634217
16.

Stratifying risk and targeting immunosuppressive strategies.

Russ G.

Transplant Proc. 2008 Dec;40(10 Suppl):S60-2. doi: 10.1016/j.transproceed.2008.10.002.

PMID:
19100912
17.

Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.

Singh SK, Gupta AK, Jha V, Kohli HS, Gupta KL, Minz M, Sakhuja V.

Transplant Proc. 2006 Sep;38(7):2088-9.

PMID:
16980008
18.

The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich.

Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, Graeb C, Jauch KW, Guba M.

Kidney Int. 2007 Jun;71(12):1271-8. Epub 2007 Feb 28.

19.

Post-transplant malignancy: reducing the risk in kidney transplant recipients.

Wu C, Shapiro R.

Expert Opin Pharmacother. 2011 Aug;12(11):1719-29. doi: 10.1517/14656566.2011.569708. Epub 2011 Apr 12. Review.

PMID:
21480821
20.

Antibody induction therapy for lung transplant recipients.

Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA.

Cochrane Database Syst Rev. 2013 Nov 27;(11):CD008927. doi: 10.1002/14651858.CD008927.pub2. Review.

PMID:
24282128

Supplemental Content

Support Center